Effect of mesenchymal stem cells derived exosomes and green tea polyphenols on acetic acid induced ulcerative colitis in adult male albino rats

Mohamady, Rania; Elwia, Sania; Wafa, Sahar M. Abo El; Mohamed, Mohamed Abdelrahman

doi:10.1080/01913123.2022.2039825

Cited by 8 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…112,137 Mesenchymal stem cell-derived exosomes (MSC-Exos) have been used as a new strategy for the therapy of ulcerative colitis. 138,139 Compared with traditional treatment methods, MSC-Exos have excellent biocompatibility, active targeting ability, the ability to aggregate at specific lesion sites for effect, and no toxic side effects. 140 However, intravenous therapy for ulcerative colitis may cause some exosomes to remain in the liver and lungs, resulting in poor therapeutic effect.…”

Section: Application Of Engineered Exosomesmentioning

confidence: 99%

Research Advances of Engineered Exosomes as Drug Delivery Carrier

Huang,

Wu,

Liao

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Exosomes are nanoscale vesicles secreted by living cells that have similar membrane composition to parental cells and carry a variety of proteins, lipids, and nucleic acids. Therefore, exosomes have certain biological activities and play an important role in intercellular communication. On the basis of its potential as a carrier for drug delivery systems, exosomes have been engineered to compensate for the shortage of natural exosomes through various engineering strategies for improving drug delivery efficiency, enhancing targeting to tissues and organs, and extending the circulating half-life of exosomes. This review focuses on the engineered exosomes loading drugs through different strategies, discussions on exosome surface modification strategies, and summarizes the advantages and disadvantages of different strategies. In addition, this review provides an overview of the recent applications of engineered exosomes in a number of refractory and relapsable diseases. This review has the potential to provide a reference for further research and development of engineered exosomes.

show abstract

Section: Application Of Engineered Exosomesmentioning

confidence: 99%

Research Advances of Engineered Exosomes as Drug Delivery Carrier

Huang,

Wu,

Liao

et al. 2023

ACS Omega

View full text Add to dashboard Cite

show abstract

“…These metabolic outcomes emerge from the mitigation of fatty acid oxidation, mediated by the obesity-associated gene and peroxisome proliferator-activated receptor alpha (PPARα) (Cheng et al 2021 ). Another study has revealed that miR-96-5p-shuttled BM-MSC-EXOs activated mitochondrial autophagy through suppressing its downstream caspase-2 (the governing player in high-fat diet-induced NASH) (El-Derany and AbdelHamid 2021 ). Kang et al ( 2022 ) and Du et al ( 2022 ) demonstrated that NASH was dramatically mitigated after using human umbilical cord MSCs-EXOs with the involvement of miR-24-3p/ Kelch-like ECH-associated protein 1(Keap1)/PPARα and nuclear factor erythroid 2-related factor 2 (Nrf2)/NADPH quinone oxidoreductase1 pathways.…”

Section: Applications Of Msc-evs In Different Models Of Gi Diseasesmentioning

confidence: 99%

Innovative preconditioning strategies for improving the therapeutic efficacy of extracellular vesicles derived from mesenchymal stem cells in gastrointestinal diseases

Didamoony,

Soubh,

Atwa

et al. 2023

Inflammopharmacol

View full text Add to dashboard Cite

Gastrointestinal (GI) diseases have become a global health issue and an economic burden due to their wide distribution, late prognosis, and the inefficacy of recent available medications. Therefore, it is crucial to search for new strategies for their management. In the recent decades, mesenchymal stem cells (MSCs) therapy has attracted attention as a viable option for treating a myriad of GI disorders such as hepatic fibrosis (HF), ulcerative colitis (UC), acute liver injury (ALI), and non-alcoholic fatty liver disease (NAFLD) due to their regenerative and paracrine properties. Importantly, recent studies have shown that MSC-derived extracellular vesicles (MSC-EVs) are responsible for most of the therapeutic effects of MSCs. In addition, EVs have revealed several benefits over their parent MSCs, such as being less immunogenic, having a lower risk of tumour formation, being able to cross biological barriers, and being easier to store. MSC-EVs exhibited regenerative, anti-oxidant, anti-inflammatory, anti-apoptotic, and anti-fibrotic effects in different experimental models of GI diseases. However, a key issue with their clinical application is the maintenance of their stability and efficacy following in vivo transplantation. Preconditioning of MSC-EVs or their parent cells is one of the novel methods used to improve their effectiveness and stability. Herein, we discuss the application of MSC-EVs in several GI disorders taking into account their mechanism of action. We also summarise the challenges and restrictions that need to be overcome to promote their clinical application in the treatment of various GI diseases as well as the recent developments to improve their effectiveness. Graphical abstract A representation of the innovative preconditioning techniques that have been suggested for improving the therapeutic efficacy of MSC-EVs in GI diseases. The pathological conditions in various GI disorders (ALI, UC, HF and NAFLD) create a harsh environment for EVs and their parents, increasing the risk of apoptosis and senescence of MSCs and thereby diminishing MSC-EVs yield and restricting their large-scale applications. Preconditioning with pharmacological agents or biological mediators can improve the therapeutic efficacy of MSC-EVs through their adaption to the lethal environment to which they are subjected. This can result in establishment of a more conducive environment and activation of numerous vital trajectories that act to improve the immunomodulatory, reparative and regenerative activities of the derived EVs, as a part of MSCs paracrine system. ALI, acute liver injury; GI diseases, gastrointestinal diseases; HF, hepatic fibrosis; HSP, heat shock protein; miRNA, microRNA; mRNA, messenger RNA; MSC-EVs, mesenchymal stem cell-derived extracellular vesicles; NAFLD, non-alcoholic fatty liver disease; UC, ulcerative colitis.

show abstract